NEWS RELEASES

Printer Friendly Version View printer-friendly version
<< Back
Science Magazine Ranks Millennium Among Top Biopharma Companies In The World

CAMBRIDGE, Mass., October 8, 2010Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine. Each year the publication administers a survey to determine the top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries worldwide. In this year’s survey results, Millennium was ranked number 4. Millennium has previously ranked in the top 10, ranking 5 in 2009 and 8 in 2008.
 
“We are very excited to be ranked yet again as a top place to work by Science,” said Steve Gansler, Senior Vice President, Millennium. “Millennium has always been known locally for its commitment to groundbreaking research in oncology and the unique culture that retains top talent within the industry. This ranking solidifies our position globally as a best place to work for scientists interested in doing their best science under a bold vision of aspiring to cure cancer.”

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and research-driven environment. The 2010 survey sought to identify the companies with the best reputations as employers based on more than 2,444 survey responses from readers of Science and other respondents in industry. Approximately 27 percent of survey participants came from outside the United States. Survey results were independently analyzed by The Brighton Consulting Group. To read the complete article appearing in the 8 October 2010 issue of Science with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2010_10_08/science.opms.r1000096.
 
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, http://www.millennium.com/.

Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com/.

Contacts:
Manisha Pai 
(617) 551-7877
Manisha.Pai@mpi.com

Lauren Musto
(617) 551-7848
Lauren.Musto@mpi.com